New Medical Technologies
13
21M
10
2
0.23
6
- Areas of investment
Summary
The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2000. Opposing the other organizations, this New Medical Technologies works on 21 percentage points more the average amount of lead investments. The top amount of exits for fund were in 2018. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies. The fund is generally included in less than 2 deals every year.
Among the various public portfolio startups of the fund, we may underline Cytos, Thommen Medical, Arpida AG The fund has exact preference in some founders of portfolio startups. Among the most successful fund investment fields, there are Medical Device, Manufacturing. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the New Medical Technologies, startups are often financed by Venrock, Techno Venture Management, Skyline Ventures. The meaningful sponsors for the fund in investment in the same round are HealthCap, Aventic Partners AG, Alta Berkeley Venture Partners. In the next rounds fund is usually obtained by Credit Suisse First Boston, HealthCap, HBM Healthcare Investments AG.
Investments analytics
Analytics
- Total investments
- 13
- Lead investments
- 2
- Exits
- 6
- Follow on index
- 0.23
- Investments by industry
- Biotechnology (10)
- Health Care (9)
- Pharmaceutical (6)
- Medical (6)
- Biopharma (5) Show 6 more
- Investments by region
-
- Switzerland (7)
- United States (3)
- Germany (1)
- Canada (1)
- United Kingdom (1)
- Peak activity year
- 2000
- Number of Minotaurs
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 25
- Avg. valuation at time of investment
- 33M
- Group Appearance index
- 0.85
- Avg. company exit year
- 8
- Avg. multiplicator
- 0.28
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Cytos | 26 Jul 2000 | Biotechnology, Hospital, Pharmaceutical | Early Stage Venture | 32M | Switzerland, Zurich |
| Viron Therapeutics | 19 Jan 2000 | Early Stage Venture | 7M | Ontario, London, Canada |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.